Frank Reed

A potential new FDA initiative aims to drastically reduce response times to drug sponsors, but details remain unconfirmed. Is this a sign of a changing regulatory landscape?

A leading materials science company unveils a potential breakthrough in tire technology, offering an alternative to a chemical linked to the deaths of coho salmon and other aquatic life. The innovation faces regulatory hurdles and competition.

European regulators endorse a novel pertussis vaccine, offering a targeted approach to bolster immunity and address waning protection against the highly contagious respiratory illness.

Molecular Designs launches a new multiplex PCR panel designed to accelerate HPV research, offering improved efficiency and accuracy for scientists studying cancer prevention and treatment.

The FDA's approval of POHERDY marks a significant step forward in affordable cancer care, introducing the first biosimilar alternative to PERJETA for HER2-positive breast cancer patients.

A promising higher dose of Biogen’s SMA therapy, Spinraza, hit a snag with the FDA, despite positive trial data. The company navigates a crowded market with rivals innovating gene therapies and oral treatments.

For years, dental health was seen as separate from overall well-being. Now, research reveals a powerful connection – and why your dentist may be key to preventing serious illness.

As CBD gains popularity, a growing need exists for informed patient-doctor discussions. One company is stepping up to bridge the knowledge gap and empower better healthcare conversations.

As personalized health gains traction, Parsley Health’s new Longevity Labs program offers a deeper dive into biomarkers—but how does it stack up against a rapidly growing field of competitors?

A new patient guide from leading organizations seeks to demystify genetic testing for prostate cancer, a rapidly evolving field offering personalized treatment options. But who benefits, and what are the potential drawbacks?

Direct-to-consumer epigenetic testing is booming, promising insights into biological age and health risks. But experts raise questions about accuracy, interpretation, and whether the science truly delivers on its promises.

A new direct-to-consumer epigenetic test aims to map aging at the organ level. We investigate the science, the cost, and the implications for the burgeoning longevity market.